Antihypertensives and COVID-19: Literature review
DOI:
https://doi.org/10.33448/rsd-v10i6.15977Keywords:
Antihypertensive Agents; Angiotensin-Converting Enzyme Inhibitors; Hypertension; SARS-CoV-2; COVID-19.Abstract
Hypertensive patients with COVID-19 are susceptible to complications of the disease, so this study aimed to analyze the action of drugs that act on Angiotensin (TA) in the presence of COVID-19 in comparison with other antihypertensives, as well as to identify the main ones. evidence on the subject presented so far. It is an integrative literature review containing 34 articles selected according to the inclusion criteria, between January / 2020 to February / 2021, in the PubMed, Embase, Scopus and Web of Science databases. The results do not show a causal relationship between the increase in COVID-19 infection and the use of RAAS inhibitors, but a possible protective effect of these against the severe manifestation of the disease due to the inhibition of the pro-inflammatory diseases of AT II. Thus, about ⅔ of the studies defended the continuity of use and the protection factor of RAAS blockers to the detriment of the other classes of antihypertensive drugs that do not modulate RAAS. It was found, then, that antihypertensive treatment should be maintained, as it does not worsen the prognosis in the face of Sars-CoV-2 infection. However, the studies are mainly observational and, therefore, cannot establish strong causal relationships. For this reason, robust randomized controlled trials are needed to better understand this topic.
References
Abajo, F. J., Rodríguez-Martín, S., Lerma, V., Mejía-Abril, G., Aguilar, M., & García-Luque, A., et al. (2020). Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 395(10238), 1705-1714. https://doi.org/10.1016/S0140-6736(20)31030-8.
Alnajjar, R., Mostafa, A., Kandeil, A., & Al-Karmalawy, A. A. (2020). Molecular docking, molecular dynamics, and in vitro studies reveal the potential of angiotensin II receptor blockers to inhibit the COVID-19 main protease. Heliyon. 6(12), e05641. https://doi.org/10.1016/j.heliyon.2020.e05641.
Antwi-Amoabeng, D., Beutler, B. D., Moody, A. E., Kanji, Z., Gullapalli, N., & Rowan, C. J. (2020). Management of hypertension in COVID-19. World J Cardiol. 12(5), 228-230. https://doi.org/10.4330/wjc.v12.i5.228.
Cadegiani, F. A., Goren, A., & Wambier, C. G. (2020). Spironolactone can provide protection against SARS-CoV-2: androgen targets, angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin-aldosterone system (RAAS). J Med Hypotheses. 143, 110112. https://doi.org/10.1016 / j.mehy.2020.110112.
Cheng, H., Wang, Y., & Wang, L-Q. (2020). Organ‐protective effect of angiotensin‐converting enzyme 2 and its effect on the prognosis of COVID‐19. J Med Virol. 92, 726 - 730. https://doi.org/10.1002/jmv.25785.
Dantas, T. C. de A. ., Gomes, A. C. A. ., Lima, I. P. C. ., Lucas , B. B. ., Aguiar, M. R. de ., Cavalcanti, T. C. de H. ., Pinheiro, F. I. ., Rêgo, A. C. M. ., & Araújo-Filho, I. (2021). Corticosteroid therapy in patients with severe COVID-19. Research, Society and Development, 10(1), e58910112114. https://doi.org/10.33448/rsd-v10i1.12114.
Delpino, M. V., & Quarleri, J. (2020) SARS-CoV-2 Pathogenesis: Imbalance in the Renin-Angiotensin System Favors Lung Fibrosis. Front Cell Infect Microbiol. 10(340). doi: https://doi.org/10.3389/fcimb.2020.00340.
Fang, L., Karakiulakis, G., & Roth, M. (2020). Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 8(4), e21. https://doi.org/10.1016/S2213-2600(20)30116-8.
Gao, C., Cai, Y., Zhang, K., Zhou, L., & Zhang, Y., et al. (2020). Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J. 41(22), 2058-2066. https://doi.org/10.1093/eurheartj/ehaa433.
Goes, A. B., Cardoso, B. B., Tavares, F. A., Monte, R. R., et al. (2020). COVID-19 and Nervous System: Under Estimated Clinical and Prognostic Aspects. International Journal of Neurology Neurotherapy, 7(100), 1-7. https://doi.org/10.23937/2378-3001/1410100.
Grasselli, G., Greco, M., Zanella, A., Albano, G., Antonelli, M., & Bellani, G., et al. (2020). COVID-19 Lombardy ICU Network. Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA Intern Med. 180(10), 1345-1355. https://doi.org/10.1001/jamainternmed.2020.3539.
Guan, W., Ni, Z., Hu, Y., Liang, W., Ou, C., & He, J., et al. (2020). Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 382, 1708-20. https://doi.org/10.1056/NEJMoa2002032.
Gurwitz, D. (2020). Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics. Drug Dev Res. 81, 537-540. https://doi.org/10.1002/ddr.21656.
Hypertension ECo. (2020). Position Statement of the ESC Council on Hypertension on ACEInhibitors and Angiotensin Receptor Blockers [internet]. [acesso em 2021 Fev 20]. Disponível em: https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-councilon-hypertension-on-ace-inhibitors-and-ang.
Jakhmola, S., Indari, O., Baral, B., Kashyap, D., Varshney, N., Das A., Chatterjee, S., & Jha, H. C. (2020) Comorbidity Assessment Is Essential During COVID-19 Treatment. Front Physiol. 11(984). https://doi.org/10.3389/fphys.2020.00984.
Kim, J., Kim, D. W., Kim, K. I., Kim, H. B., Kim, J. H., & Lee, Y. G., et al. (2020) Korean Society of Hypertension. Compliance of Antihypertensive Medication and Risk of Coronavirus Disease 2019: a Cohort Study Using Big Data from the Korean National Health Insurance Service. J Korean Med Sci. 35(25), e232. https://doi.org/10.3346/jkms.2020.35.e232.
Libby, P., & Lüscher, T. (2020). COVID-19 is, in the end, an endothelial disease. Eur Heart J. 41(32), 3038-3044. https://doi.org/10.1093/eurheartj/ehaa623.
Malhotra, A., Hepokoski, M., McCowen, K. C. & Y-J Shyy J. (2020). ACE2, Metformin, and COVID-19. iScience. 23(9), 101425. https://doi.org/10.1016/j.isci.2020.101425.
Mancia, G., Rea, F., Ludergnani, M., Apolone, G., & Corrao, G. (2020). Blockers of the renin-angiotensin-aldosterone system and the risk of Covid-19. N Engl J Med. 382(25), 2431-2440. https://doi.org/10.1056 / NEJMoa2006923.
Marin, G. H. (2020). Facts and reflections on COVID-19 and anti-hypertensives drugs. Drug Discov Ther. 14(2), 105-106. https://doi.org/10.5582/ddt.2020.01017.
Meng, J., Xiao, G., Zhang, J., He, X., & Ou, M., et al. (2020). Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 9(1), 757-760. https://doi.org/10.1080/22221751.2020.1746200.
Monte, R. R., Tavares, F. A., Cardoso, B. B., Goes, A. B., et al. (2020). Covid-19 Pandemic and Health Professionals: Practical Approaches. International Journal of Critical Care Emergency Medicine, 6(108), 1-9. https://doi.org/10.23937/2474-3674/1510108.
Nejat, R., & Sadr, A. S. (2020). Are losartan and imatinib effective against SARS-CoV2 pathogenesis? A pathophysiologic-based in silico study. In Silico Pharmacol. 9(1), 1. https://doi.org/10.1007/s40203-020-00058-7.
Organização Pan-Americana de Saúde; Organização Mundial da Saúde [homepage na internet]. (2021). Folha informativa COVID-19 - Escritório da OPAS e da OMS no Brasil. [acesso 2021 Fev 09]. Disponível em: https://www.paho.org/pt/covid19.
Ramírez-Sagredo, A., Ramírez-Reyes, A., Ocaranza, M. P., Chiong, M., Riquelme, J. A., & Jalil, J. E., et al. (2020). Anti hypertensive agents in patients with COVID-19. Rev Chil Cardiol. 39(1), 66-74. http://dx.doi.org/10.4067/S0718-85602020000100066.
Reynolds, H. R., Adhikari, S., Pulgarin, C., Troxel, A. B., Iturrate, E., & Johnson, S. B, et al. (2020). Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med. 382(25), 2441-2448. https://doi.org/10.1056/NEJMoa2008975.
Rothlin, R. P., Vetulli, H. M., Duarte, M., & Pelorosso, F. G. (2020). Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19. Drug Dev Res. 81(7), 768-770. https://doi.org/10.1002/ddr.21679.
Ruilope, L. M., Tamargo, J., & Ruiz-Hurtado, G. (2020). Renin-angiotensin system inhibitors in the COVID-19 pandemic: consequences of antihypertensive drugs. Eur Heart J. 41(22), 2067–2069. https: //doi.org/10.1093/eurheartj/ehaa487.
Salazar, M., Barochiner, J., Espeche, W., & Ennis, I. (2020). COVID-19, hipertensión y enfermedad cardiovascular [COVID-19 and its relationship with hypertension and cardiovascular disease]. Hipertens Riesgo Vasc. 37(4), 176-180. https://doi.org/10.1016/j.hipert.2020.06.003.
Sardu, C., Maggi, P., Messina, V., Iuliano, P., Sardu, A., & Iovinella, V., et al. (2020). Could Anti-Hypertensive Drug Therapy Affect the Clinical Prognosis of Hypertensive Patients With COVID-19 Infection? Data From Centers of Southern Italy. J Am Heart Assoc. 9(17), e016948. https://doi.org/10.1161/JAHA.120.016948.
Semenzato, L., Botton, J., Drouin, J., Baricault, B., Vabre, C., & Cuenot, F., et al. (2021). Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients. Hypertension. 77(3), 833-842. https://doi.org/10.1161/HYPERTENSIONAHA.120.16314.
Shibata, S., Arima, H., Asayama, K., Hoshide, S., Ichihara, A., & Ishimitsu, T., et al. (2020). Hypertension and related illnesses in the COVID-19 era: a report by the Japanese Hypertension Society Task Force on COVID-19. Hypertens Res. 43(1), 1028–1046. https://doi.org/10.1038/s41440-020-0515-0.
Singh, A. K., Gupta, R., & Misra, A. (2020). Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers. Diabetes Metab Syndr. 14(4), 283-287. https://doi.org/10.1016/j.dsx.2020.03.016.
Solaimanzadeh, I. (2020). Nifedipina e amlodipina estão associadas a mortalidade melhorada e risco reduzido de intubação e ventilação mecânica em pacientes idosos hospitalizados por COVID-19. Cureus. 12(5), e8069. https://doi.org/10.7759/cureus.8069.
Trifirò, G., Crisafulli, S., Andò, G., Racagni, G., & Drago, F. (2020). Italian Society of Pharmacology. Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)? Drug Saf. 43(6), 507-509. https://doi.org/10.1007/s40264-020-00935-2.
Trump, S., Lukassen, S., Anker, M. S., Chua, R. L., Liebig, J., & Thürmann L., et al. (2020) Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. Nat Biotechnol. https://doi.org/10.1038/s41587-020-00796-1.
Vila-Corcoles, A., Satue-Gracia, E., Ochoa-Gondar, O., Torrente-Fraga, C., Gomez-Bertomeu, F., & Vila-Rovira, A., et al. (2020). Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: A population-based cohort study in Southern Catalonia, Spain. J Clin Hypertens (Greenwich). 22(8), 1379-1388. https://doi.org/10.1111/jch.13948.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Thais Cristina Loyola da Silva; Pedro Vilar de Oliveira Villarim; Alyne Barreto Mesquita de Goés; Vitória Ribeiro Dantas Marinho; Natália Marcelino Araújo; André Luiz Costa e Silva; Amália Cinthia Meneses Rêgo; Irami Araújo-Filho
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
